Vittoria Biotherapeutics

Vittoria Biotherapeutics is a leading gene-editing cell therapy company with an exclusive license to a novel platform technology from the University of Pennsylvania. Vittoria’s technology and clinical programs aim to address current shortcomings in cell therapies, with a pipeline benefiting from advanced gene-editing technologies. The company is on track to file an IND for its lead program, Viper 101, by mid-2023. Viper 101 is a gene-edited autologous dual-cell therapy designed to meet the unmet treatment needs for T-cell lymphoma.